BACKGROUND: Molecular classification of breast cancer is commonly done to determine response to therapy and cancer prognosis. Aim of the study was to compare prevalence of molecular subtypes of breast cancer in our institute using immunohistochemistry, including Ki-67, and correlate it with clinical and pathological prognostic factors. RESULTS: 300 cases of invasive breast cancer were included in the study. Average age at time of diagnosis was 44 years and average size of tumor was 3.4cms. Invasive ductal carcinoma was the most common histological type (75.3%). The most common molecular subtype was triple negative (34.3%) followed by Luminal B (33.4%), luminal A (17%) and Her-2 positive (15.3%). Large size and poorly differentiated tumors were predominantly triple negative tumors while lymph node metastasis was most commonly seen in Her-2 positive tumors. CONCLUSION: Molecular subtype of breast carcinoma should routinely be done for all cases of carcinoma breast as it allows to identify aggressive tumors and target therapy accordingly.
BACKGROUND: Molecular classification of breast cancer is commonly done to determine response to therapy and cancer prognosis. Aim of the study was to compare prevalence of molecular subtypes of breast cancer in our institute using immunohistochemistry, including Ki-67, and correlate it with clinical and pathological prognostic factors. RESULTS: 300 cases of invasive breast cancer were included in the study. Average age at time of diagnosis was 44 years and average size of tumor was 3.4cms. Invasive ductal carcinoma was the most common histological type (75.3%). The most common molecular subtype was triple negative (34.3%) followed by Luminal B (33.4%), luminal A (17%) and Her-2 positive (15.3%). Large size and poorly differentiated tumors were predominantly triple negative tumors while lymph node metastasis was most commonly seen in Her-2 positive tumors. CONCLUSION: Molecular subtype of breast carcinoma should routinely be done for all cases of carcinoma breast as it allows to identify aggressive tumors and target therapy accordingly.
Authors: Nisha Hariharan; T Subramanyeshwar Rao; Chandra K Naidu; K V V N Raju; Senthil Rajappa; Santa Ayyagari; M V T Krishnamohan; Sudha Murthy; Aparna Suryadevara; Naren Boleneni Journal: J Adolesc Young Adult Oncol Date: 2019-06-28 Impact factor: 2.223
Authors: Sara Bustreo; Simona Osella-Abate; Paola Cassoni; Michela Donadio; Mario Airoldi; Fulvia Pedani; Mauro Papotti; Anna Sapino; Isabella Castellano Journal: Breast Cancer Res Treat Date: 2016-05-07 Impact factor: 4.872